Mathew S. Maurer

机构：Boston University, Brigham and Women's Hospital, Boston Medical Center, NewYork–Presbyterian Hospital, Alnylam Pharmaceuticals (United States), Columbia University Irving Medical Center, New York Hospital Queens, Amyloidosis Foundation, Columbia University · ORCID：0000-0001-5400-5008

发表论文 547 篇 · 总被引 24804 次 · h-index 73

代表论文

• Coramitug, a Humanized Monoclonal Antibody for the Treatment of Transthyretin Amyloid Cardiomyopathy: A Phase 2, Randomized, Multicenter, Double-Blind, Placebo-Controlled Trial (2025 · Circulation · 被引 15)
• Cardiac Resynchronization Therapy, Remodeling, and Outcome in Patients With Amyloid Transthyretin Cardiomyopathy (2025 · Journal of the American Heart Association · 被引 4)
• Changing Patterns of Diagnosis and Survival in Transthyretin Cardiac Amyloidosis: A Multicenter Cohort Study (2025 · Journal of the American Heart Association · 被引 3)
• Temporal Trends in Incidence and Prevalence of Transthyretin Amyloid Cardiomyopathy in the United States (2026 · Journal of the American Heart Association · 被引 1)
• Abstract 4350904: Comprehensive Plasma Transcriptomics Profiling Identifies a Small Set of Circulating MicroRNA Biomarkers to Distinguish Hypertrophic Cardiomyopathy from Other Cardiomyopathies with Left Ventricular Hypertrophy (2025 · Circulation · 被引 1)
• Endothelial Cell‐Related Proteins in Plasma Predict Major Adverse Cardiovascular Events and Worsening Heart Failure in Patients With Hypertrophic Cardiomyopathy (2025 · Journal of the American Heart Association · 被引 1)